MENLO PARK, Calif., Sept. 28, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that data from its DRM04 Phase 3 clinical program in patients with primary axillary hyperhidrosis (excessive underarm sweating) will be presented in a late-breaking news session at the 25thEuropean Academy of Dermatology and Venereology (EADV) Congress, taking place in Vienna, Austria, Sept. 28 – Oct. 2. The data will be presented in an oral presentation by David Pariser, M.D., a professor at Eastern Virginia Medical School’s Department of Dermatology. In addition, an overview of the CIMZIA® (certolizumab pegol) Phase 3 clinical development program for moderate-to-severe chronic plaque psoriasis will be presented at a poster session.
“We look forward to presenting updated data from our Phase 3 clinical program for DRM04 that adds to the growing body of evidence demonstrating the therapy’s potential treatment impact on patients with axillary hyperhidrosis,” said Eugene A. Bauer, M.D., chief medical officer of Dermira.
Abstracts of Interest:
Title: DRM04 for the treatment of axillary hyperhidrosis: Primary results from the ATMOS-1 and ATMOS-2 Phase 3 randomized controlled trials
Date and Time: October 1, 2016; 9:00 a.m. – 9:15 a.m. CET [12:00 a.m. – 12:15 a.m. PDT]
Session: Late-Breaking News; D3T01.1
Abstract Number: D3T01.1E – Oral Presentation
Title: Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: an overview of 3 randomized controlled trials
Date and Time: September 28, 2016 – October 2, 2016
Location: Available in ePoster area
ePoster ID: P2113
Abstract Number: VIE16ABS-1285
Dermira is a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases. Dermira’s portfolio includes three late-stage product candidates that target significant unmet needs and market opportunities: CIMZIA® (certolizumab pegol), in Phase 3 development in collaboration with UCB Pharma S.A. for the treatment of moderate-to-severe chronic plaque psoriasis; DRM04, in Phase 3 development for the treatment of primary axillary hyperhidrosis (excessive underarm sweating); and DRM01, in Phase 2b development for the treatment of facial acne vulgaris. Dermira is headquartered in Menlo Park, California. For more information, please visit www.dermira.com.
In addition to our filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, we use our website (www.dermira.com) and LinkedIn page (https://www.linkedin.com/company/dermira-inc-) as channels of distribution of information about our company, our product candidates, our planned financial and other announcements, our attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our LinkedIn page in addition to following our SEC filings, press releases, public conference calls and webcasts.
The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. This press release contains forward-looking statements that involve substantial risks and uncertainties, including statements with respect to the potential treatment impact of DRM04 on patients with axillary hyperhidrosis. These statements deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to the design, implementation and outcomes of Dermira’s clinical trials; Dermira’s anticipated pre-NDA meeting with the FDA for DRM04; Dermira’s dependence on third-party clinical research organizations, manufacturers and suppliers; Dermira’s ability to obtain regulatory approval for its product candidates; and Dermira’s ability to continue to stay in compliance with applicable laws and regulations. You should refer to the section entitled “Risk Factors” set forth in Dermira’s Annual Report on Form 10-K, Dermira’s Quarterly Reports on Form 10-Q and other filings Dermira makes with the SEC from time to time for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Furthermore, such forward-looking statements speak only as of the date of this press release. Dermira undertakes no obligation to publicly update any forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise, except as required by law.
Senior Director, Head of Corporate Communications
Chief Operating Officer and Chief Financial Officer
Robert H. UhlWestwicke Partners